XML 40 R29.htm IDEA: XBRL DOCUMENT
v3.25.2

Segment (Tables) | 6 Months Ended
--- | ---
Jun. 30, 2025
Segment Reporting [Abstract] |
Schedule of Segment Reporting Information, by Segment | Information about reported segment revenue, measures of segment profit or loss, significant segment expenses and reconciliation to income from operations was as follows (in thousands):
| Three Months Ended June 30, |  | Six Months Ended June 30,
| 2025 |  | 2024 |  | 2025 |  | 2024
Revenue: |  |  |  |  |  |  |
Testing revenue | $ | 122,263 |  |  | $ | 106,970 |  |  | $ | 229,572 |  |  | $ | 197,273 |
Product revenue | 3,598 |  |  | 3,906 |  |  | 7,178 |  |  | 7,443 |
Biopharmaceutical and other revenue | 4,303 |  |  | 3,552 |  |  | 7,887 |  |  | 6,556 |
Total revenue | 130,164 |  |  | 114,428 |  |  | 244,637 |  |  | 211,272 |
Cost of revenue: |  |  |  |  |  |  |
Cost of testing revenue: |  |  |  |  |  |  |
Laboratory supplies and reagents expense | 15,304 |  |  | 13,326 |  |  | 28,369 |  |  | 25,244 |
Sample collection expense | 3,494 |  |  | 3,164 |  |  | 6,320 |  |  | 6,221 |
Compensation expense | 6,023 |  |  | 5,139 |  |  | 11,634 |  |  | 10,354 |
Other cost of testing revenue (1) | 4,173 |  |  | 3,479 |  |  | 7,559 |  |  | 6,325 |
Allocation of facilities and IT expenses | 3,413 |  |  | 2,812 |  |  | 6,785 |  |  | 5,755 |
Total cost of testing revenue | 32,407 |  |  | 27,920 |  |  | 60,667 |  |  | 53,899 |
Cost of product revenue: |  |  |  |  |  |  |
Product costs | 705 |  |  | 628 |  |  | 813 |  |  | 1,891 |
License fees and royalties | 307 |  |  | 314 |  |  | 631 |  |  | 751 |
Other cost of product revenue (2) | 515 |  |  | 800 |  |  | 1,309 |  |  | 1,623 |
Allocation of facilities and IT expenses | 222 |  |  | 132 |  |  | 418 |  |  | 253 |
Total cost of product revenue | 1,749 |  |  | 1,874 |  |  | 3,171 |  |  | 4,518 |
Cost of biopharmaceutical and other revenue: |  |  |  |  |  |  |
Compensation expense | 1,652 |  |  | 2,072 |  |  | 2,892 |  |  | 3,533 |
Other cost of biopharmaceutical and other revenue (3) | 1,462 |  |  | 1,271 |  |  | 2,506 |  |  | 2,221 |
Allocation of facilities and IT expenses | 458 |  |  | 469 |  |  | 872 |  |  | 896 |
Total cost of biopharmaceutical and other revenue | 3,572 |  |  | 3,812 |  |  | 6,270 |  |  | 6,650 |
Intangible asset amortization - cost of revenue | 2,667 |  |  | 2,909 |  |  | 5,252 |  |  | 5,824 |
Gross profit | 89,769 |  |  | 77,913 |  |  | 169,277 |  |  | 140,381 |
Operating expenses: |  |  |  |  |  |  |
Research and development: |  |  |  |  |  |  |
Compensation expense | 9,063 |  |  | 8,365 |  |  | 18,812 |  |  | 17,450 |
Direct research and development expense | 3,292 |  |  | 5,243 |  |  | 7,434 |  |  | 9,117 |
Other research and development expenses (4) | 1,880 |  |  | 1,339 |  |  | 3,692 |  |  | 2,857 |
Allocation of facilities and IT expenses | 2,029 |  |  | 1,518 |  |  | 4,046 |  |  | 3,006 |
Total research and development | 16,264 |  |  | 16,465 |  |  | 33,984 |  |  | 32,430 |
Selling and marketing: |  |  |  |  |  |  |
Compensation expense | 17,601 |  |  | 17,081 |  |  | 35,236 |  |  | 34,703 |
Direct marketing expense | 1,478 |  |  | 2,048 |  |  | 2,188 |  |  | 3,186 |
Other selling and marketing expenses (5) | 3,696 |  |  | 3,212 |  |  | 7,549 |  |  | 6,627 |
Allocation of facilities and IT expenses | 2,541 |  |  | 1,875 |  |  | 4,797 |  |  | 3,482 |
Total selling and marketing | 25,316 |  |  | 24,216 |  |  | 49,770 |  |  | 47,998 |
General and administrative: |  |  |  |  |  |  |
Compensation expense | 21,260 |  |  | 23,107 |  |  | 41,433 |  |  | 40,866 |
Other general and administrative expenses (6) | 19,734 |  |  | 15,444 |  |  | 41,624 |  |  | 30,481 |
Allocation of facilities and IT expenses | (8,663) |  |  | (6,806) |  |  | (16,918) |  |  | (13,392) |
Total general and administrative | 32,331 |  |  | 31,745 |  |  | 66,139 |  |  | 57,955 |
Impairment of assets | 20,505 |  |  | — |  |  | 20,505 |  |  | 429 |
Intangible asset amortization - operating expenses | 621 |  |  | 881 |  |  | 1,243 |  |  | 1,619 |
Other income, net | (6,518) |  |  | (2,755) |  |  | (11,042) |  |  | (5,503) |
Income tax provision | 2,230 |  |  | 1,627 |  |  | 2,611 |  |  | 1,583 |
Net income (loss) | $ | (980) |  |  | $ | 5,734 |  |  | $ | 6,067 |  |  | $ | 3,870 |
________________ (1)Other cost of testing revenue includes cytopathology services, depreciation and amortization and other expenses. (2)Other cost of product revenue includes license fees and royalties, depreciation and amortization and other expenses. (3)Other cost of biopharmaceutical and other revenue includes license fees and royalties, depreciation and amortization and other expenses. (4)Other research and development expenses includes depreciation and amortization and other expenses. (5)Other selling and marketing expenses includes travel, entertainment, conference and other expenses. (6)Other general and administrative expenses includes professional fees, information technology expense, occupancy costs, depreciation and amortization, contingent consideration and other expenses.

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration